The Viet Nam Competition Authority eyed the nation’s pharmaceutical sector at a recent conference, where the regulator addressed the seeming paradox of a low concentration rate but increasing pharmaceutical companies. Reports say the head of the regulator’s Competition Supervision and Management Department spoke about the troublesome pattern of rising prices in the industry, despite the fact that there are nine times more distributors of pharmaceuticals than there are producers – a figure that implies a low concentration rate, usually associated with high competition and lower prices. Tran Phuong Lan stated that merger and acquisition activity could potentially increase competition by allowing foreign rivals into the market.
Featured News
Paramount Wants States to Post $1.9 Billion Bond Over Warner Bros. Deal
Aug 17, 2026 by
CPI
California Bill to Cap Concert Ticket Resale Prices Dies in Senate
Aug 17, 2026 by
CPI
Six Banks Agree to $86.4 Million Deal in Mexican Bond Antitrust Case
Aug 17, 2026 by
CPI
ByteDance Reaches Hollywood Copyright Accord Over AI Tools
Aug 17, 2026 by
CPI
Court Backs Kansas in Nexstar-Tegna Antitrust Fight
Aug 17, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Antitrust Compliance
Jul 20, 2026 by
CPI
Your Antitrust Compliance Program: A Strong Voice in Your Defense
Jul 20, 2026 by
Joe Murphy
Antitrust Compliance for the AI Pricing Era
Jul 20, 2026 by
Alejandra Uria & Andre Geverola
Race to Report: Antitrust Leniency in the Whistleblower Era
Jul 20, 2026 by
Brian R. Faerstein & Nicole H. Sprinzen
Antitrust-By-Design: Competition Compliance in Digital Markets
Jul 20, 2026 by
Marcos Drummond Malvar, Gabriela Costa Carvalho Forsman & Luciana Mendes